RCS - Cambridge Cognition - Investor Presentation

Cambridge Cognition HoldingsAnnouncement

05/10/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201005:nRSE0252Ba

RNS Number : 0252B  Cambridge Cognition Holdings PLC  05 October 2020

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Investor Presentation

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that CEO
Matthew Stork and CFO Nick Walters will provide a live investor presentation
on Wednesday 14 October at 6.00pm London time.

 

The presentation is open to all existing and potential shareholders.  Those
wishing to attend should email zach.cohen@investor-focus.co.uk
(mailto:zach.cohen@investor-focus.co.uk) and they will be provided with log in
details.  There will be the opportunity for participants to ask questions at
the end of the presentation.  Questions can also be emailed to the above
address ahead of the presentation.

 

Enquiries:

 

 Cambridge Cognition Holdings plc          Tel: 01223 810 700
 Matthew Stork, Chief Executive Officer    press@camcog.com
 Nick Walters, Chief Financial Officer

 finnCap Ltd (Nomad and Joint Broker)      Tel: 020 7220 0500
 Geoff Nash/ Simon Hicks                   (Corporate Finance)
 Alice Lane/ Manasa Patil                  (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)    Tel: 020 3903 7715
 David Poutney/ James Serjeant

 IFC Advisory Ltd (Financial PR and IR)    Tel: 020 3934 6630
 Tim Metcalfe/ Graham Herring/ Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a neuroscience technology company developing digital
health products to better understand, detect and treat conditions affecting
brain health. The Company's software products assess cognitive health in
patients worldwide to improve clinical trial outcomes, identify and stratify
patients early and improve global efficiency in pharmaceutical and healthcare
industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMIBPTMTAMBFM